nach oben

PharmacoEconomics

Erschienen in:

01.07.2007 | Review Article

Retrospective Economic and Outcomes Analyses Using Non-US Databases

A Review

verfasst von: Dr Lizheng Shi, Eric Q Wu, Meredith Hodges, Andrew Yu, Howard Birnbaum

Erschienen in: PharmacoEconomics | Ausgabe 7/2007

Einloggen, um Zugang zu erhalten

Abstract

Retrospective database analyses pose a series of methodological challenges, some of which are unique to their data sources, particularly in countries outside the US. This study aimed to qualitatively review the methodological challenges of using non-US databases to conduct retrospective economic and outcomes research studies.

We conducted a MEDLINE search to obtain a sample of literature published after the year 2000 on retrospective analyses using non-US databases. We reviewed all relevant components of the selected articles in accordance with the checklist proposed for retrospective database studies by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Task Force and identified issues found in the data sources, methods, study designs, statistics and sources of possible threats to internal and external validity.

We found a wide variation in the quality of studies in terms of outcome definitions, patient selection criteria, data collection methods, sample sizes, risk adjustment methods, potential measurement errors and external validity of the studies. Few economic studies included information on indirect cost components because of a lack of relevant data.

The quality of non-US retrospective database analyses varied. Future such analyses may be improved if researchers implement the checklist developed by the ISPOR Task Force on Retrospective Database Studies.

Birnbaum HG, Cremieux PY, Greenberg PE, et al. Using healthcare claims data for outcomes research and pharmacoeconomic analyses. Pharmacoeconomics 1999; 16 (1): 1–8PubMedCrossRef

Ward RA, Brier ME. Retrospective analyses of large medical databases: what do they tell us? J Am Soc Nephrol 1999; 10: 429–432PubMed

Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observation studies, and the hierarchy of research designs. N Engl J Med 2000 Jun 22; 342: 1887–1892PubMedCrossRef

Benson K, Hartz AJ. A comparison of observation studies and randomized, controlled trials. N Engl J Med 2000 Jun 22; 342: 1878–1886PubMedCrossRef

Motheral B, Brooks J, Clark MA, et al. A checklist for retrospective database studies: report of the ISPOR Task Force on Retrospective Databases. Value Health 2003 Mar–Apr; 6: 90–97PubMedCrossRef

Jick S, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol 2000; 136 (10): 1231–1236PubMedCrossRef

Moride Y, Ducruet T, Boivin JF, et al. Utilization of non-steroidal anti-inflammatory drugs in Quebec: adherence to the Canadian consensus on prescription guidelines. Can J Clin Pharmacol 2005 Jun 17; 12 (2): 201–211

Martel MJ, Rey E, Beauchesne MF, et al. Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study. BMJ 2005 Jan 19; 330: 230–233PubMedCrossRef

Quach C, Collet JP, LeLorier J. Acute otitis media in children: a retrospective analysis of physician prescribing patterns. Br J Clin Pharmacol 2004; 57 (4): 500–505PubMedCrossRef

10.

Mahmud SM, Fong B, Fahmy N, et al. Effect of preoperative delay on survival in patients with bladder cancer undergoing cystectomy in Quebec: a population based study. J Urol 2006 Jan; 175: 78–83PubMedCrossRef

11.

Vanasse A, Dagenais P, Niyonsenga T, et al. Bone mineral density measurement and osteoporosis treatment after fragility fracture in older adults: regional variation and determinants of use in Quebec. BMC Musculoskelet Disord 2005 Jun 21; 6: 33PubMedCrossRef

12.

Nelson CH, Park J. The nature and correlates of unmet health care needs in Ontario, Canada. Soc Sci Med 2006 May; 62 (9): 2291–2300PubMedCrossRef

13.

Wang JL, Patten SB, Williams JV, et al. Help-seeking behaviors of individuals with mood disorders. Can J Psychiatry 2005 Sep; 50 (10): 652–659PubMed

14.

Nguyen CT, Fournier L, Bergeron L, et al. Correlates of depressive and anxiety disorders among young Canadians. Can J Psychiatry 2005 Sep; 50 (10): 620–628PubMed

15.

Vasiliadis HM, Lesage A, Adair C, et al. Service use for mental health reasons: cross-provincial differences in rates, determinants, and equity of access. Can J Psychiatry 2005 Sep; 50 (10): 614–619PubMed

16.

Beck CA, Williams JV, Wang JL, et al. Psychotropic medication use in Canada. Can J Psychiatry 2005 Sep; 50 (10): 605–613PubMed

17.

Kairouz S, Nadeau L, Siou GL. Area variations in the prevalence of substance abuse and gambling behaviors and problems in Quebec: a multilevel analysis. Can J Psychiatry 2005 Sep; 50 (10): 591–598PubMed

18.

Patten SB. The impact of antidepressant treatment on population health: synthesis of data from two national data sources in Canada. Popul Health Metr 2004 Nov 1; 2 (1): 9PubMedCrossRef

19.

Vissandjee, B, Desmeules, M, Zheynuan, C, et al. 2004Integrating socio-economic determinants of Canadian women’s healthBMC Women’s Health1S34CrossRef

20.

Ross N. Community belonging and health. Health Rep 2002 Mar; 13 (3): 33–39PubMed

21.

Currie SR, Patten SB, Williams JV, et al. Comorbidity of major depression with substance use disorders. Can J Psychiatry 2005 Sep; 50 (10): 660–666PubMed

22.

Bergh J, Holmquist M. Who should not receive adjuvant chemotherapy? International databases. J Natl Cancer Inst Monogr 2001; 30: 103–108PubMedCrossRef

23.

Graves N, Birrell F, Whitby M. Effect of pressure ulcers on length of hospital stay. Infect Control Hosp Epidemiol 2005 Mar; 26 (3): 293–297PubMedCrossRef

24.

Walland M. Glaucoma treatment in Australia: changing patterns of therapy. Clin Experiment Ophthalmol 2004; 32: 590–596PubMedCrossRef

25.

Monnet DL, Molstad S, Cars O. Defined daily doses of antimicrobials reflect antimicrobial prescriptions in ambulatory care. J Antimicrob Chemother 2004 Apr 29; 53: 1109–1111PubMedCrossRef

26.

Rahme E, Joseph L, Kong SX, et al. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. Br J Clin Pharmacol 2001; 52: 185–192PubMedCrossRef

27.

Ricordeau P, Weill A, Vallier N, et al. The prevalence and cost of diabetes in metropolitan France: what trends between 1998 and 2000? Diabetes Metab 2003 Nov; 29 (5): 497–504PubMedCrossRef

28.

Gandjour A, Kleinschmit F, Lauterbach KW, et al. European comparison of costs and quality in the prevention of secondary complications in type 2 diabetes mellitus (2000–2001). Diabet Med 2002; 19: 594–601PubMedCrossRef

29.

Berto P, Tinuper P, Viaggi S, et al. Cost-of-illness in Italy: data from a multicentre observational study (Episcreen). Pharmacoeconomics 2000; 17 (2): 197–208PubMedCrossRef

30.

Didoni G, Grottol S, Gasco V, et al. Cost-of-illness study in acromegalic patients in Italy. J Endocrinol Invest 2004 Dec; 27: 1034–1039PubMed

31.

Leong RW, Smith DW, Garas G, et al. Aciclovir or ganciclovir universal prophylaxis of cytomegalovirus infection in liver transplantation: an economic analysis. Intern Med J 2004; 34: 410–415PubMedCrossRef

32.

Bassi A, Dodd S, Williamson P, et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53: 1471–1478PubMedCrossRef

33.

Dedes KJ, Szucs TD, Bodis S, et al. Management and costs of treating lung cancer patients in a university hospital. Pharmacoeconomics 2004; 22 (7): 435–444PubMedCrossRef

34.

Mashiba S, Takahashi T, Hayashi N, et al. Features of patients with influenza virus infection examined in the emergency department of a university hospital in north-western Japan. J Int Med Res 2004; 32: 331–336PubMed

35.

Wong MK, Arjandas M, Ching LK, et al. Osteoporotic hip fractures in Singapore: costs and patient’s outcome. Ann Acad Med Singapore 2002; 31 (1): 3–7PubMed

36.

Lindgren P, Jonsson B, Redaelli A, et al. Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer. Pharmacoeconomics 2002; 20 (2): 101–108PubMedCrossRef

37.

Remak E, Brazil L. Cost of managing women presenting with stage IV breast cancer in the United Kingdom. Br J Cancer 2004 Jun 8; 91: 77–83PubMedCrossRef

38.

Jansen AC, van Aalst-Cohen ES, Tanck MW, et al. Genetic determinants of cardiovascular disease risk in familial hypercholesterolemia. Arteriosclero Thromb Vascu Biol 2005; 25 (7): 1475–1481CrossRef

39.

Ash AS, Ellis RP, Pope GC, et al. Using diagnoses to describe populations and predict costs. Health Care Fin Rev 2000; 21: 7–28

40.

Clark DO, Von Korff M, Saunders K, et al. A chronic disease score with empirically derived weights. Med Care 1995; 33: 783–795PubMedCrossRef

41.

Deyo AR, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613–619PubMedCrossRef

42.

Gilmer T, Kronick R, Fishman P, et al. The Medicaid Rx model: pharmacy-based risk adjustment for public programs. Med Car 2001; 39 (11): 1188–1102CrossRef

43.

Lezzoni L, Ash AS, Daley J, et al. Risk adjustment for measuring healthcare outcomes. 2nd ed. Chicago (IL): Health Administration Press, 1997

44.

Kronick R, Gilmer T, Dreyfus T, et al. Improving health-based payment for Medicaid beneficiaries. CDPS Health Care Fin Rev 2000; 21: 29–64

45.

Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. J Am Stat Assoc 1996; 91: 444–454CrossRef

46.

Crown W, Obenchain R, Englehart L, et al. Application of sample selection models to outcomes research: the case of evaluating effects of antidepressant therapy on resource utilization. Stat Med 1998; 17: 1943–1958PubMedCrossRef

47.

D’Agostino R. Tutorial in biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17 (19): 2265–2281PubMedCrossRef

Titel: Retrospective Economic and Outcomes Analyses Using Non-US Databases
A Review
verfasst von: Dr Lizheng Shi
Eric Q Wu
Meredith Hodges
Andrew Yu
Howard Birnbaum
Publikationsdatum: 01.07.2007
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 7/2007
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200725070-00003

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Retrospective Economic and Outcomes Analyses Using Non-US Databases

A Review

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2007

Direct and Indirect Costs Attributable to Alcohol Consumption in Germany

The Use of Disease-Specific Outcome Measures in Cost-Utility Analysis

A Cost-Effectiveness Analysis of First-Line Controller Therapies for Persistent Asthma

Cost-Utility Analysis in China: Differences and Difficulties Compared with Developed Countries

Perspectives on Dynamic Optimisation and Control Theory in Treating Hyperlipidaemia

Cost Considerations in the Treatment of Colorectal Cancer